Radiological outcome of bone disease in multiple myeloma patients pre- and post therapy

References

1. 1.↵
   World Health Organization. Global Cancer Observatory: Cancer Today. [Updated 2020; 2021 March 5] Available from: https://gco.iarc.fr/today
2. 2.↵
   1. Hillengass J,
   2. Moulopoulos LA,
   3. Delorme S,
   4. Koutoulidis V,
   5. Mosebach J,
   6. Hielscher T, et al.

   Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J 2017; 7: e599.

   OpenUrl
3. 3.↵
   1. Rajkumar SV,
   2. Dimopoulos MA,
   3. Palumbo A,
   4. Blade J,
   5. Merlini G,
   6. Mateos MV, et al.

   International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–e548.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Moreau P,
   2. Attal M,
   3. Caillot D,
   4. Macro M,
   5. Karlin L,
   6. Garderet L, et al.

   Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol 2017; 35: 2911–2918.

   OpenUrl
5. 5.↵
   1. Bannas P,
   2. Kröger N,
   3. Adam G,
   4. Derlin T

   . [Modern imaging techniques in patients with multiple myeloma]. RoFo 2013; 185: 26–33.

   OpenUrl
6. 6.↵
   1. Sachpekidis C,
   2. Mai EK,
   3. Goldschmidt H,
   4. Hillengass J,
   5. Hose D,
   6. Pan L, et al.

   (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med 2015; 40: e300–e307.

   OpenUrl
7. 7.↵
   1. Zamagni E,
   2. Tacchetti P,
   3. Cavo M

   . Imaging in multiple myeloma: How? When? Blood 2019; 133: 644–651.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Baffour FI,
   2. Glazebrook KN,
   3. Kumar SK,
   4. Broski SM

   . Role of imaging in multiple myeloma. Am J Hematol 2020; 95: 966–977.

   OpenUrlCrossRef
9. 9.↵
   1. Cavo M,
   2. Terpos E,
   3. Nanni C,
   4. Moreau P,
   5. Lentzsch S,
   6. Zweegman S, et al.

   Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18: e206–e217.

   OpenUrlPubMed
10. 10.↵
    1. Haghighat S

    . The Role of 18F-FDG-PET/CT Scan in the management of multiple myeloma. APJCC 2020; 5: 119–123.

    OpenUrl
11. 11.↵
    1. Rajkumar SV

    . Multiple myeloma: 2018 update on diagnosis, risk stratification, and management. Am J Hematol 2018; 93: 981–1114.

    OpenUrlPubMed
12. 12.↵
    1. Kosmala A,
    2. Bley T,
    3. Petritsch B

    . Imaging of multiple myeloma. RoFo 2019; 191: 805–816.

    OpenUrl
13. 13.↵
    1. Rasch S,
    2. Lund T,
    3. Asmussen JT,
    4. Lerberg Nielsen A,
    5. Faebo Larsen R,
    6. Østerheden Andersen M, et al.

    Multiple myeloma associated bone Disease. Cancers (Basel) 2020; 12: 2113.

    OpenUrl
14. 14.↵
    1. Dammacco F,
    2. Rubini G,
    3. Ferrari C,
    4. Vacca A,
    5. Racanelli V

    . ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med 2015; 15: 1–18.

    OpenUrl
15. 15.↵
    1. Ziogas DC,
    2. Dimopoulos MA,
    3. Kastritis E

    . Prognostic factors for multiple myeloma in the era of novel therapies. Expert Rev Hematol 2018; 11: 863–879.

    OpenUrl